Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.House Approves Chemical Security Legislation
The House of Representatives has approved new and stringent standards for chemical site security, pushing forth with efforts to mandate product substitution in a misguided attempt to safeguard
The House of Representatives has approved new and stringent standards for chemical site security, pushing forth with efforts to mandate product substitution in a misguided attempt to safeguard
The endorsement comes less than a year after the vaccine’s first licensure and will accelerate global access to Synflorix. Jean Stephenne, CEO of GSK, said: “The vaccine helps
NexBio in collaboration with scientists at the centers for disease control and prevention (CDC), has published two studies that suggests DAS181 (Fludase) may play a potentially important role
The randomised phase II trial treats patients with unresectable or metastatic soft tissue sarcoma in the front- and second-line setting. Patients are randomised either to doxorubicin (the only
Xoma has expanded its development strategy for its XOMA 052 antibody to interleukin-1 beta (IL-1 beta) to include effects on cholesterol lowering, reducing plaque deposits and damage to
Halozyme has reported the insulin variability study results that demonstrate reduced intrasubject absorption variability for the combination of lispro, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro
Graceway Pharmaceuticals (Graceway) has acquired the worldwide license, including related regulatory filings and intellectual properties from Gilead Sciences, to its’s investigational molecule, GS 9191, for topical use. GS
Arkema has presented to its Balan facility’s trade union representatives a plan to shut-down a 30,000 ton PVC production unit on the site in order to strengthen the
Covidien has completed the previously announced acquisition of Aspect Medical Systems for an aggregate consideration of approximately $210m, net of cash and short-term investments acquired. The tender offer
Threshold Pharmaceuticals has disclosed clinical trial results related to its clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society (CTOS)